Qanatpharma

Private

MunichHealthcare & Life Scienceshttps://www.qanatpharma.com/

Last Round

VC Round

Jul 1, 2023

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Qanatpharma is a clinical-stage biopharmaceutical company that develops innovative therapies for diseases characterized by microvascular dysfunction.

Sector

Healthcare & Life Sciences

Verticals

Pharma Supply Chain, Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

drug discoverybiopharmaceuticalAI drug discoveryin-silico drug discoverycomputational biologygenerative AIclinical trialsbiotechmolecular designtherapeutic targetsmulti-omicspharma supply chaindrug developmentpharma logistics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Qanatpharma Comparables

Compare Qanatpharma with similar companies based on industry and business-model similarity.

Qanatpharma comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Aphaia Pharma	36%
HeartBeat.bio AG	33%
Variant Bio	33%

View all Comparables

Qanatpharma Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
VC Round	Jul 1, 2023

View all Funding Rounds

Key People

Founding team and executive leadership

Steffen-Sebastian Bolz

Executive Board Member And Chief Scientific And Medical Officer, Founder

Founding Team

Christian Albrecht

CEO

Executive Team

Philipp Trepte

Chief Technology Officer, Managing Director at Qanatpharma Germany GmbH

Executive Team

Guenther Jucho

Chief Financial Officer

Executive Team

View all key people

Qanatpharma Investors

Notable investors and investment history

Qanatpharma investors
Investor	Rounds
Ventura BioMed Investors	VC Round

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 5, 2026
Grew 30% quarter-over-quarter, from 10 to 13 employees.

View all signals

Qanatpharma Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Qanatpharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Qanatpharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersMunich

Employee Range13

Year Founded2017

Last FundingJul 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.